At AbbVie, they have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today, a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.
With almost 40 years of experience in biotechnology, Amgen is a pioneer and expert in manufacturing biological medicines across different therapeutic areas, including inflammation. By developing several originator molecules and biosimilars in this field, Amgen will continuously deepen its commitment to patients and offer new treatment options to HCPs.
Biogen is a pioneer company in neuroscience. As one of the world’s first global biotechnology companies, Biogen has the leading portfolio to treat multiple sclerosis, introduced the first and only approved treatment for spinal muscular atrophy and continuously invests in advancing care in neuroscience. Biogen also manufactures and commercializes three anti-TNF biosimilars of advanced biologics in Europe. More than 100’000 patients have been treated with one of those biosimilars, contributing to expanding access to patients and the future of healthcare sustainability having generated estimated healthcare cost savings of 800 million Euro annually across Europe.
"Celltrion Healthcare is a biopharmaceutical company leader and pioneer specialized in development, production and global marketing & distribution of biologic products including biosimilars.
Biosimilars, which Celltrion Healthcare has been offering, have the potential to enlarge access to a wider number of patients and are contributing to reduce the health-care cost. The amount saved can be extensively used for other health-care benefits for patients and medical specialists.
Celltion Healthcare proudly supports the BIRD in its mission to stimulate research in the field of Inflammatory Bowel disease."
Innovative drugs for bowel and liver diseases.
Their pharmaceuticals are used successfully to treat inflammatory bowel disease and cholestatic liver disease.
They focus on modern formulations and specially designed delivery systems to ensure targeted release of the active drug.
Ferring is a research-driven, specialty biopharmaceutical company with operations in 55 countries.
Ferring develops, manufactures and markets pharmaceutical and biopharmaceutical drugs that span the human life cycle and has in particular developed excellence in peptide and endocrine research.
Ferring philosophy, â€œPeople come first at Ferringâ€, is the cornerstone of our business. This means our patients, their families and advisers, healthcare professionals, our employees and those on whose lives we can make a positive impact with our expertise and resources.
Improving peopleâ€™s health through medicine on the bodyâ€™s own terms; that is our core business intention.
At Ferring we understand that our primary responsibility is the delivery of therapies that bring long-lasting benefiets to patients and in some instances save lives. We also understand that we need to do this in a way that maximizes the positive impact we have on our communities and the environment in which we operate.
Our long-standing expertise in pharmaceuticals and devices allows us to support clinical staff and care professionals as they provide the best therapy for patients.
As a global healthcare company with a decentralized organization, Fresenius Kabi is ideally placed to meet the needs of customers and patients worldwide.
Every day, more than 37,000 employees share one passion for "caring for life". It is our commitment to what matters most in healthcare: Improving the patients’ quality of life.
Galapagos is a Belgian clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.
Our mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, we discover which proteins ('targets') play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms. Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.
We're more than 30,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease to HIV, Alzheimer's disease to cancer, we are committed to issues that touch everyone's lives.
We want to make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
Our mission is to discover, develop and provide innovative products and services that save and improve lives around the world.
At Mundipharma we are committed to developing a diverse portfolio of medicines that meet societal needs. We aim to conduct our business in an ethical, transparent and responsible way, doing whatâ€™s right for our employees and partners, while contributing to the communities within which we operate. We look at things from a different perspective and are experts at identifying and developing the potential of medical innovations and biosimilars to help improve patientâ€™s lives in meaningful ways and at an affordable cost to providers.
Bringing transformative medicines to patients for over a century
We are proud to be able to help 22 million patients worldwide every year.
Founded in 1906, Norgine is a leading European specialist pharmaceutical company with a strong global network of partnerships.
This enables us to acquire, develop and commercialise innovative products that make a real difference to the lives of patients around the world.
Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
Pfizer has a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.
As the world’s largest biotech company we work intensely to understand how diseases differ down to the molecular level so we can develop new tests and medicines that prevent, diagnose and treat diseases, and bring them to the patients who need them.
We develop breakthrough medicines, improving the standard of care across oncology, immunology, infectious diseases, ophthalmology and neuroscience. We are also the world leader in in vitro diagnostics. These combined strengths in diagnostics and pharmaceuticals empower us to deliver a personalised healthcare strategy with the aim to fit the right treatment to the right patient.
Sandoz, a Novartis division, is a global leader in biosimilars and generic pharmaceuticals.
Our mission is to discover new ways to improve and extend people’s lives.
Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine.
Our global portfolio comprises approximately 1 000 molecules, covering all major therapeutic areas.
Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.
Takeda Belgium SCA
We strive towards better health for patients worldwide through leading innovation in medicine.
We, the members of the Takeda Group, pledge to act with integrity at all times, especially when facing difficulties or challenges. "Integrity" refers to our compliance with the highest ethical standards, our fairness and honesty in conducting every activity, and our perseverance in pursuing the ideal forms for our operations and management. Through the demonstration of these qualities, we show our commitment to building trust and confidence in all the people around us, and our determination to continue to expand the business. These empower our progress in our global endeavours to fulfil our mission to "strive towards better health for patients worldwide through leading innovation in medicine".
Together with our highest ethical standards it has become a vital part of our management â€“ for today and tomorrow.
Vifor Pharma België nv
Vifor Pharma Group, is a global pharmaceutical company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions. The company’s goal is to be a global leader in iron deficiency, nephrology and cardio-renal therapies and strives to help patients around the world with severe and chronic diseases to lead better, healthier lives.
Vifor Pharma is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. Vifor Pharma Group has production sites in Switzerland and Portugal as well as a dynamic network of affiliates and partners offering broad market coverage all over the world.